Nav: Home

Glioma subtypes determine how the dangerous tumors spread, evade anti-angiogenic treatment

April 27, 2018

A multi-institutional research team has identified a new mechanism by which the dangerous brain tumors called gliomas develop resistance to anti-angiogenic treatment. The team's report, published online in Cancer Cell, describes finding how different molecular subtypes of glioma cells use different strategies to spread through the brain and how anti-angiogenic treatment selects for a treatment-resistant cellular subtype.

"Despite massive basic and clinical research efforts, the treatment of glioblastoma and other malignant gliomas remains one of the most challenging tasks in clinical oncology," says Rakesh Jain, PhD, director of the Edwin L. Steele Laboratories for Tumor Biology in the Massachusetts General Hospital (MGH) Department of Radiation Oncology and co-senior author of the report. "Glioblastomas are highly vascularized and interact closely with pre-existing blood vessels for oxygen and nutrients. They also contain a very diverse population of cells, with characteristics of stem cell and other cells found within the brain, and may use different strategies to recruit or access blood vessels, depending on the local microenvironment and on treatments that are applied."

Previous studies have revealed several ways that gliomas can migrate within the brain - including "co-option" in which single cells migrate along blood vessels or as dense clusters that lead to the formation of new blood vessels. To investigate mechanisms underlying these two strategies, the research team, primarily comprised of investigators from MGH and the University of California San Francisco (https://www.ucsf.edu/) (USCF), focused on a protein called Olig2, normally involved in the development of brain cells called oligodendrocytes and expressed in most glioma subtypes.

Oligodendrocyte precursors (OPCs) that express Olig2 can act as glioma progenitors; and within OPCs, signaling controlled by a protein called Wnt7 is known to play a role in embryonic vascular development within the brain, including the cells' migration along blood vessels. The team's series of experiments revealed the following:
  • Olig2-positive glioma cells invade brain tissue by single-cell co-option without affecting the existing vasculature. Increased Wnt7 expression within those cells was required for that strategy.
  • Olig2-negative cells grow as clusters around blood vessels - which show increased size and density - and express high levels of the angiogenic factor VEGF. Olig2-negative gliomas exhibit a breakdown in the blood brain barrier and increased activation of innate immune cells, leading to neuroinflammation.
  • In a mouse model of Olig2-positive gliomas that express Wnt7, treatment with drugs that inhibit Wnt or another protein in the Wnt pathway induced glioma cells to lose contact with blood vessels and form the sort of clusters usually seen in Olig2-negative gliomas.
  • In mice implanted with Olig2-positive, Wnt7-expressing cells from human gliomas, treatment of late-stage tumors with a Wnt inhibitor and the chemotherapy drug temozolomide improved survival compared with temozolomide alone.
  • Treatment of glioma cell lines with the VEGF inhibitor bevacizumab promoted single-cell, vascular co-option, most likely by increasing Olig2 expression. Analysis of bevacizumab-resistant cells - including paired samples from human patients taken before and after bevacizumab treatment - supported the conclusion is that anti-VEGF treatment selected for the Olig2-positive, Wnt-expressing cells that use that vascular strategy.


"We have discovered how Wnt signaling drives the process of single-cell, vascular co-option in gliomas, a mechanism that is strongly induced by anti-angiogenic treatment," says Jain, the Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School.
-end-
Co-senior author David Rowich, MD, PhD, ScD, of UCSF and the University of Cambridge in the U.K., adds, "These findings have significant therapeutic implications for our understanding of heterogeneity in glioma and how tumor components exploit alternative strategies to interact successfully with the vasculature despite anti-angiogenic treatment. Our identification of the Olig2/Wnt7 vessel co-option pathway reveals a potential target for future combination therapies."

The co-lead authors are Amelie Griveau, PhD, UCSF, and Giorgio Seano, PhD, Steele Labs, MGH Radiation Oncology. Support for the study includes SPORE grants P50 CA097257 and P50 CA165962, and grants R35 CA197743 and P01 CA080124 from the National Cancer Institute; grants from the Bryan's Dream Foundation, Pediatric Brain Tumor Foundation, Loglio Foundation, Howard Hughes Medical Institute, the Wellcome Trust, the National Foundation for Cancer Research and the Harvard Ludwig Cancer Center.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals, earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service and returned to the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Blood Vessels Articles:

Study: Use of prefabricated blood vessels may revolutionize root canals
Researchers at OHSU in Portland, Oregon, have developed a process by which they can engineer new blood vessels in teeth, creating better long-term outcomes for root canal patients and clinicians.
New findings on formation and malformation of blood vessels
In diseases like cancer, diabetes, rheumatism and stroke, a disorder develops in the blood vessels that exacerbates the condition and obstructs treatment.
Targeting blood vessels to improve cancer immunotherapy
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.
Reprogrammed blood vessels promote cancer spread
Tumor cells use the bloodstream to spread in the body.
Neurons modulate the growth of blood vessels
A team of researchers at Karlsruhe Institute of Technology shake at the foundations of a dogma of cell biology.
Sensor for blood flow discovered in blood vessels
The PIEZO1 cation channel translates mechanical stimulus into a molecular response to control the diameter of blood vessels.
Blood vessels control brain growth
Blood vessels play a vital role in stem cell reproduction, enabling the brain to grow and develop in the womb, reveals new UCL research in mice.
No blood vessels without cloche
After 20 years of searching, scientists discover the mystic gene controlling vessel and blood cell growth in the embryo.
New way of growing blood vessels could boost regenerative medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Regenerating blood vessels gets $2.7 million grant
Biomedical engineers in the Cockrell School of Engineering at The University of Texas at Austin have received $2.7 million in funding to advance a treatment that regenerates blood vessels.

Related Blood Vessels Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".